Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cytokinetics, Incorporated - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CYTK
Nasdaq
2836
www.cytokinetics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cytokinetics, Incorporated
Cytokinetics Names Robert E. Landry to Board of Directors
- Feb 11th, 2025 12:30 pm
Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts
- Feb 8th, 2025 2:05 pm
Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Feb 5th, 2025 9:00 pm
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 4th, 2025 9:00 pm
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
- Jan 30th, 2025 2:55 pm
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
- Jan 30th, 2025 12:30 pm
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
- Jan 29th, 2025 5:02 pm
What Are Analysts Talking About Cytokinetics (CYTK)?
- Jan 27th, 2025 9:50 pm
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
- Jan 23rd, 2025 4:19 pm
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
- Jan 22nd, 2025 8:43 pm
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
- Jan 21st, 2025 12:30 pm
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
- Jan 13th, 2025 12:30 pm
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 6th, 2025 9:00 pm
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
- Dec 23rd, 2024 12:30 pm
Why Cytokinetics Stock Was a Nearly 5% Winner Today
- Dec 20th, 2024 10:25 pm
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
- Dec 20th, 2024 5:00 am
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
- Dec 19th, 2024 11:37 am
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
- Dec 6th, 2024 4:31 pm
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
- Dec 4th, 2024 5:30 pm
Sector Update: Health Care Stocks Mixed Late Afternoon
- Dec 3rd, 2024 8:41 pm
Scroll